| Year |
Citation |
Score |
| 2016 |
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, ... ... Scher HI, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England Journal of Medicine. PMID 27433846 DOI: 10.1056/Nejmoa1603144 |
0.302 |
|
| 2016 |
Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Molina A, Kheoh T, McCormack R, ... ... Scher HI, et al. Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European Urology. PMID 27289566 DOI: 10.1016/j.eururo.2016.05.023 |
0.325 |
|
| 2016 |
Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene SB, Heller G, Marrinucci D, et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. Jama Oncology. PMID 27262168 DOI: 10.1001/Jamaoncol.2016.1828 |
0.369 |
|
| 2016 |
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, ... ... Scher HI, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27141017 DOI: 10.1093/Annonc/Mdw180 |
0.374 |
|
| 2016 |
Scher HI. Defining new standards of care for men with prostate cancer. Lancet (London, England). 387: 1135-7. PMID 27025318 DOI: 10.1016/S0140-6736(15)01235-0 |
0.316 |
|
| 2016 |
Fizazi K, Chi KN, de Bono JS, Gomella LG, Miller K, Rathkopf DE, Ryan CJ, Scher HI, Shore ND, De Porre P, Londhe A, McGowan T, Pelhivanov N, Charnas R, Todd MB, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. European Urology. PMID 26965562 DOI: 10.1016/j.eururo.2016.02.035 |
0.348 |
|
| 2016 |
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26903579 DOI: 10.1200/Jco.2015.64.2702 |
0.367 |
|
| 2016 |
Morris MJ, Rathkopf DE, Novotny W, Gibbons JA, Peterson A, Khondker Z, Ouatas T, Scher HI, Fleming MT. Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26858312 DOI: 10.1158/1078-0432.CCR-15-2638 |
0.362 |
|
| 2016 |
Scher HI. Defining new standards of care for men with prostate cancer The Lancet. 387: 1135-1137. DOI: 10.1016/S0140-6736(15)01235-0 |
0.316 |
|
| 2015 |
Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, Rathkopf DE, Fizazi K, Kantoff PW, Li J, Azad AA, Eigl BJ, Heng DY, Joshua AM, de Bono JS, ... Scher HI, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26685010 DOI: 10.1093/annonc/mdv594 |
0.343 |
|
| 2015 |
Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, Krupa R, Graf R, Schreiber N, Nanus DM, Tagawa ST, Marrinucci D, Dittamore R, Scher HI. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26671992 DOI: 10.1158/1078-0432.CCR-15-0137 |
0.337 |
|
| 2015 |
Fizazi K, Flaig TW, Stöckle M, Scher HI, de Bono JS, Rathkopf DE, Ryan CJ, Kheoh T, Li J, Todd MB, Griffin TW, Molina A, Ohlmann CH. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26609008 DOI: 10.1093/annonc/mdv545 |
0.368 |
|
| 2015 |
Teo MY, Scher HI. Urological cancer: CHAARTED/GETUG 12-docetaxel in non-castrate prostate cancers. Nature Reviews. Clinical Oncology. PMID 26552950 DOI: 10.1038/nrclinonc.2015.192 |
0.355 |
|
| 2015 |
Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, et al. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. European Urology. PMID 26508309 DOI: 10.1016/J.Eururo.2015.10.021 |
0.369 |
|
| 2015 |
Rathkopf DE, Larson SM, Anand A, Morris MJ, Slovin SF, Shaffer DR, Heller G, Carver B, Rosen N, Scher HI. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer. PMID 26178426 DOI: 10.1002/cncr.29578 |
0.315 |
|
| 2015 |
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, ... ... Scher HI, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1589-604. PMID 26041764 DOI: 10.1093/annonc/mdv257 |
0.369 |
|
| 2015 |
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, ... ... Scher HI, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 161: 1215-28. PMID 26000489 DOI: 10.1016/J.Cell.2015.05.001 |
0.353 |
|
| 2015 |
Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, ... ... Scher HI, et al. Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. European Urology. PMID 25985882 DOI: 10.1016/J.Eururo.2015.04.032 |
0.302 |
|
| 2015 |
Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, McCormack R, Burzykowski T, Kheoh T, Fleisher M, Buyse M, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1348-55. PMID 25800753 DOI: 10.1200/JCO.2014.55.3487 |
0.362 |
|
| 2015 |
Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, et al. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. The Lancet. Oncology. 16: 338-48. PMID 25701170 DOI: 10.1016/S1470-2045(15)70027-6 |
0.346 |
|
| 2015 |
Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. European Urology. PMID 25698064 DOI: 10.1016/j.eururo.2015.01.026 |
0.321 |
|
| 2015 |
Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, ... ... Scher HI, et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1356-63. PMID 25624432 DOI: 10.1200/JCO.2014.55.3875 |
0.34 |
|
| 2015 |
Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Griffin TW, Kheoh T, Ricci DS, Zelinsky K, Rathkopf DE, ... Scher HI, et al. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1621-7. PMID 25593303 DOI: 10.1158/1078-0432.CCR-14-1961 |
0.377 |
|
| 2015 |
Autio KA, Farooki A, Glezerman IG, Chan A, Schneider CW, Barr HC, Seyboth BM, Kampel LJ, Danila DC, Rathkopf DE, Slovin SF, Scher HI, Morris MJ. Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. Clinical Genitourinary Cancer. 13: e305-9. PMID 25559408 DOI: 10.1016/j.clgc.2014.11.008 |
0.331 |
|
| 2015 |
Saad F, de Bono J, Shore N, Fizazi K, Loriot Y, Hirmand M, Franks B, Haas GP, Scher HI. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. European Urology. 67: 223-30. PMID 25171902 DOI: 10.1016/J.Eururo.2014.08.025 |
0.32 |
|
| 2015 |
Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. European Urology. 67: 866-73. PMID 25018037 DOI: 10.1016/j.eururo.2014.06.042 |
0.302 |
|
| 2014 |
Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, ... ... Scher HI, et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3391-9. PMID 25225437 DOI: 10.1200/JCO.2013.54.5954 |
0.34 |
|
| 2014 |
Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, ... ... Scher HI, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 159: 176-87. PMID 25201530 DOI: 10.1016/J.Cell.2014.08.016 |
0.363 |
|
| 2014 |
Bastos DA, Dzik C, Rathkopf D, Scher HI. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer. Oncology (Williston Park, N.Y.). 28: 693-9. PMID 25140626 |
0.339 |
|
| 2014 |
Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, Villanueva J, Saghatelian A, Assel M, Vickers AJ, Eastham JA, Scher HI, Carver BS, Lilja H, Tempst P. Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Molecular & Cellular Proteomics : McP. 13: 3082-96. PMID 25056937 DOI: 10.1074/Mcp.M114.038836 |
0.35 |
|
| 2014 |
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, ... ... Scher HI, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. The New England Journal of Medicine. 371: 424-33. PMID 24881730 DOI: 10.1056/Nejmoa1405095 |
0.346 |
|
| 2014 |
Scher HI. Building on Prostate Cancer Working Group 2 to change the paradigm from palliation to cure. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. e204-12. PMID 24857104 DOI: 10.14694/EdBook_AM.2014.34.e204 |
0.325 |
|
| 2014 |
Chang AJ, Autio KA, Roach M, Scher HI. High-risk prostate cancer-classification and therapy. Nature Reviews. Clinical Oncology. 11: 308-23. PMID 24840073 DOI: 10.1038/nrclinonc.2014.68 |
0.304 |
|
| 2014 |
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. Oncology. 15: 700-12. PMID 24831977 DOI: 10.1016/S1470-2045(14)70189-5 |
0.35 |
|
| 2014 |
Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, ... ... Scher HI, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European Urology. 66: 815-25. PMID 24647231 DOI: 10.1016/J.Eururo.2014.02.056 |
0.365 |
|
| 2014 |
Ryan CJ, Peng W, Kheoh T, Welkowsky E, Haqq CM, Chandler DW, Scher HI, Molina A. Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer and Prostatic Diseases. 17: 192-8. PMID 24637537 DOI: 10.1038/pcan.2014.8 |
0.361 |
|
| 2014 |
Sternberg CN, de Bono JS, Chi KN, Fizazi K, Mulders P, Cerbone L, Hirmand M, Forer D, Scher HI. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 429-34. PMID 24478320 DOI: 10.1093/annonc/mdt571 |
0.347 |
|
| 2014 |
Goodman OB, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 17: 34-9. PMID 24080993 DOI: 10.1038/pcan.2013.41 |
0.357 |
|
| 2014 |
Bastos DA, Dzik C, Rathkopf D, Scher HI. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer Oncology (United States). 28. |
0.339 |
|
| 2013 |
Bianchini D, Omlin A, Pezaro C, Lorente D, Ferraldeschi R, Mukherji D, Crespo M, Figueiredo I, Miranda S, Riisnaes R, Zivi A, Buchbinder A, Rathkopf DE, Attard G, Scher HI, et al. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British Journal of Cancer. 109: 2579-86. PMID 24169353 DOI: 10.1038/bjc.2013.619 |
0.334 |
|
| 2013 |
Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers CL, Scher HI. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3525-30. PMID 24002508 DOI: 10.1200/JCO.2013.50.1684 |
0.345 |
|
| 2013 |
Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European Journal of Cancer (Oxford, England : 1990). 49: 3648-57. PMID 23973186 DOI: 10.1016/j.ejca.2013.07.144 |
0.353 |
|
| 2013 |
Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, Allen-Freda E, Mishra KK, Porro MG, Scher HI, Wilding G. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 72: 537-44. PMID 23820963 DOI: 10.1007/S00280-013-2224-8 |
0.377 |
|
| 2013 |
Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, Scher HI, Zheng D, Sawyers CL. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine. 19: 1023-9. PMID 23817021 DOI: 10.1038/Nm.3216 |
0.348 |
|
| 2013 |
Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, Grant RP, de Bono JS, Scher HI. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2791-8. PMID 23816964 DOI: 10.1200/JCO.2012.45.4595 |
0.369 |
|
| 2013 |
Morris MJ, Autio KA, Basch EM, Danila DC, Larson S, Scher HI. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Seminars in Oncology. 40: 375-92. PMID 23806501 DOI: 10.1053/j.seminoncol.2013.04.008 |
0.352 |
|
| 2013 |
Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ. Repetitively dosed docetaxel and ¹âµÂ³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer. 119: 3186-94. PMID 23765638 DOI: 10.1002/cncr.28103 |
0.324 |
|
| 2013 |
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5182-91. PMID 23714732 DOI: 10.1158/1078-0432.Ccr-13-0231 |
0.34 |
|
| 2013 |
Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, Williamson MJ, Lacuna K, Aksnes AK, Larson SM, Scher HI, Morris MJ. Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 40: 1384-93. PMID 23653243 DOI: 10.1007/s00259-013-2427-6 |
0.368 |
|
| 2013 |
Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1813-21. PMID 23535954 DOI: 10.1093/annonc/mdt107 |
0.354 |
|
| 2013 |
Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG. β4 Integrin signaling induces expansion of prostate tumor progenitors. The Journal of Clinical Investigation. 123: 682-99. PMID 23348745 DOI: 10.1172/Jci60720 |
0.333 |
|
| 2013 |
Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer Journal (Sudbury, Mass.). 19: 43-9. PMID 23337756 DOI: 10.1097/PPO.0b013e318282635a |
0.35 |
|
| 2013 |
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, ... ... Scher HI, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine. 368: 138-48. PMID 23228172 DOI: 10.1056/Nejmoa1209096 |
0.317 |
|
| 2013 |
Sternberg CN, Molina A, North S, Mainwaring P, Fizazi K, Hao Y, Rothman M, Gagnon DD, Kheoh T, Haqq CM, Cleeland C, de Bono JS, Scher HI. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1017-25. PMID 23152362 DOI: 10.1093/annonc/mds585 |
0.368 |
|
| 2013 |
Danila DC, Scher HI. Molecular Biomarkers for Patients with Castration-Resistant Prostate Cancer: Validating Assays Predictive of Tumor Response The Path From Biomarker Discovery to Regulatory Qualification. 71-80. DOI: 10.1016/B978-0-12-391496-5.00009-0 |
0.333 |
|
| 2012 |
Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, ... ... Scher HI, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. The Lancet. Oncology. 13: 1210-7. PMID 23142059 DOI: 10.1016/S1470-2045(12)70473-4 |
0.357 |
|
| 2012 |
Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The Lancet. Oncology. 13: 1105-13. PMID 23059047 DOI: 10.1016/S1470-2045(12)70263-2 |
0.343 |
|
| 2012 |
Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, Fleisher M, Reid AH, Castro E, Sandhu SK, Barwell L, Oommen NB, Carreira S, Drake CG, Jones R, ... ... Scher HI, et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. The Lancet. Oncology. 13: 1114-24. PMID 23059046 DOI: 10.1016/S1470-2045(12)70372-8 |
0.388 |
|
| 2012 |
Gourtsoyianni S, Hwang S, Panicek DM, Zheng J, Moskowitz C, Scher H, Morris M, Hricak H. Reproducibility and clinical correlations of post-treatment changes on CT of prostate cancer bone metastases treated with chemotherapy. The British Journal of Radiology. 85: 1243-9. PMID 22919006 DOI: 10.1259/Bjr/27266976 |
0.31 |
|
| 2012 |
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine. 367: 1187-97. PMID 22894553 DOI: 10.1056/Nejmoa1207506 |
0.338 |
|
| 2012 |
Ulmert D, Vickers AJ, Scher HI, Becker C, Iversen P, Frankel D, Jensen JK, Olesen TK, Lilja H. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 50: 1993-8. PMID 22718641 DOI: 10.1515/cclm-2011-0967 |
0.31 |
|
| 2012 |
Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T, Tilley WD, Butler LM. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3562-70. PMID 22573351 DOI: 10.1158/1078-0432.Ccr-12-0782 |
0.349 |
|
| 2012 |
Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2714-9. PMID 22553195 DOI: 10.1093/Annonc/Mds078 |
0.349 |
|
| 2012 |
Autio KA, Scher HI, Morris MJ. Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Current Treatment Options in Oncology. 13: 174-88. PMID 22528368 DOI: 10.1007/s11864-012-0190-8 |
0.323 |
|
| 2012 |
Brown MS, Chu GH, Kim HJ, Allen-Auerbach M, Poon C, Bridges J, Vidovic A, Ramakrishna B, Ho J, Morris MJ, Larson SM, Scher HI, Goldin JG. Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nuclear Medicine Communications. 33: 384-94. PMID 22367858 DOI: 10.1097/MNM.0b013e3283503ebf |
0.323 |
|
| 2012 |
Thompson VC, Day TK, Bianco-Miotto T, Selth LA, Han G, Thomas M, Buchanan G, Scher HI, Nelson CC, Greenberg NM, Butler LM, Tilley WD. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. International Journal of Cancer. Journal International Du Cancer. 131: 662-72. PMID 22275114 DOI: 10.1002/ijc.26414 |
0.359 |
|
| 2012 |
Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, ... ... Scher HI, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research. 72: 1494-503. PMID 22266222 DOI: 10.1158/0008-5472.Can-11-3948 |
0.352 |
|
| 2012 |
Chen Y, Scher HI. Prostate cancer in 2011: Hitting old targets better and identifying new targets. Nature Reviews. Clinical Oncology. 9: 70-2. PMID 22231760 DOI: 10.1038/nrclinonc.2011.213 |
0.301 |
|
| 2012 |
Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, Heller G, Scher HI, Larson SM, Morris MJ. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 519-24. PMID 22231045 DOI: 10.1200/JCO.2011.36.5791 |
0.343 |
|
| 2012 |
Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. European Urology. 61: 549-59. PMID 22099611 DOI: 10.1016/j.eururo.2011.11.009 |
0.327 |
|
| 2012 |
Lowrance WT, Elkin EB, Yee DS, Feifer A, Ehdaie B, Jacks LM, Atoria CL, Zelefsky MJ, Scher HI, Scardino PT, Eastham JA. Locally advanced prostate cancer: a population-based study of treatment patterns. Bju International. 109: 1309-14. PMID 22085255 DOI: 10.1111/J.1464-410X.2011.10760.X |
0.318 |
|
| 2011 |
Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. European Urology. 60: 897-904. PMID 21802835 DOI: 10.1016/j.eururo.2011.07.011 |
0.382 |
|
| 2011 |
Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3903-12. PMID 21680546 DOI: 10.1158/1078-0432.CCR-10-2650 |
0.347 |
|
| 2011 |
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, ... ... Scher HI, et al. Abiraterone and increased survival in metastatic prostate cancer. The New England Journal of Medicine. 364: 1995-2005. PMID 21612468 DOI: 10.1056/Nejmoa1014618 |
0.35 |
|
| 2011 |
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19: 575-86. PMID 21575859 DOI: 10.1016/J.Ccr.2011.04.008 |
0.329 |
|
| 2011 |
Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nature Communications. 2: 162. PMID 21245843 DOI: 10.1038/Ncomms1159 |
0.331 |
|
| 2011 |
Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NK, Cheng S, Gan J, Gottardis M, Obermeier MT, ... ... Scher HI, et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 880-7. PMID 21131556 DOI: 10.1158/1078-0432.Ccr-10-2955 |
0.384 |
|
| 2010 |
Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, ... ... Scher HI, et al. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 2611-22. PMID 20841388 DOI: 10.1158/1055-9965.EPI-10-0555 |
0.341 |
|
| 2010 |
Roth AJ, Nelson C, Rosenfeld B, Scher H, Slovin S, Morris M, O'Shea N, Arauz G, Breitbart W. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 116: 5102-10. PMID 20665492 DOI: 10.1002/Cncr.25424 |
0.357 |
|
| 2010 |
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, ... ... Scher HI, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 18: 11-22. PMID 20579941 DOI: 10.1016/J.Ccr.2010.05.026 |
0.315 |
|
| 2010 |
Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, Gaudet MM, Fine S, Reuter V, Scher HI, Halldén C, Dutra-Clarke A, Klein RJ, Scardino PT, Eastham JA, Lilja H, et al. Susceptibility loci associated with prostate cancer progression and mortality. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2819-32. PMID 20460480 DOI: 10.1158/1078-0432.CCR-10-0028 |
0.349 |
|
| 2010 |
Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W, Scher HI. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer Cancer Chemotherapy and Pharmacology. 66: 181-189. PMID 20217089 DOI: 10.1007/s00280-010-1289-x |
0.339 |
|
| 2010 |
Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, ... ... Scher HI, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1489-95. PMID 20159823 DOI: 10.1200/JCO.2009.24.6819 |
0.367 |
|
| 2010 |
Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, ... ... Scher HI, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1496-501. PMID 20159814 DOI: 10.1200/Jco.2009.25.9259 |
0.371 |
|
| 2010 |
Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, Anand A, Cordon-Cardo C, Costa J, Scher HI. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease Bju International. 105: 462-467. PMID 19624594 DOI: 10.1111/J.1464-410X.2009.08747.X |
0.366 |
|
| 2009 |
Marrocco-Tallarigo DL, Centenera MM, Scher HI, Tilley WD, Butler LM. Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology. 2: 619-30. PMID 22112256 DOI: 10.1586/ecp.09.44 |
0.366 |
|
| 2009 |
Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P, Mendelsohn J, Scher HI. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus doxorubicin in the treatment of metastatic castration-resistant prostate cancer Clinical Genitourinary Cancer. 7: E77-E82. PMID 19815486 DOI: 10.3816/Cgc.2009.N.028 |
0.339 |
|
| 2009 |
Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. The Lancet. Oncology. 10: 981-91. PMID 19796750 DOI: 10.1016/S1470-2045(09)70229-3 |
0.32 |
|
| 2009 |
Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago phase 2 consortium Cancer. 115: 5541-5549. PMID 19711464 DOI: 10.1002/Cncr.24597 |
0.37 |
|
| 2009 |
Knudsen KE, Scher HI. Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer Clinical Cancer Research. 15: 4792-4798. PMID 19638458 DOI: 10.1158/1078-0432.Ccr-08-2660 |
0.312 |
|
| 2009 |
Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, Scher HI, Gerald WL. NF-κB regulates androgen receptor expression and prostate cancer growth American Journal of Pathology. 175: 489-499. PMID 19628766 DOI: 10.2353/Ajpath.2009.080727 |
0.345 |
|
| 2009 |
Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. European Urology. 56: 237-44. PMID 19375217 DOI: 10.1016/j.eururo.2009.03.073 |
0.352 |
|
| 2009 |
Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, ... ... Scher HI, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2436-42. PMID 19364960 DOI: 10.1200/JCO.2008.20.4164 |
0.326 |
|
| 2009 |
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, ... ... Scher HI, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York, N.Y.). 324: 787-90. PMID 19359544 DOI: 10.1126/Science.1168175 |
0.397 |
|
| 2009 |
Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M, Scher HI. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2091-7. PMID 19276271 DOI: 10.1158/1078-0432.CCR-08-2036 |
0.326 |
|
| 2009 |
Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Väänänen RM, Pettersson K, Chun FKH, Steuber T, Huland H, Guillonneau BD, Eastham JA, Scardino PT, ... ... Scher HI, et al. Circulating prostate tumor cells detected by Reverse transcription-PCR in men with localized or castration-refractory prostate cancer: Concordance with CellSearch assay and association with bone metastases and with survival Clinical Chemistry. 55: 765-773. PMID 19233911 DOI: 10.1373/clinchem.2008.117952 |
0.342 |
|
| 2009 |
Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SE, Ryan C, Logothetis C, ... Scher HI, et al. Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research Clinical Genitourinary Cancer. 7: 51-57. PMID 19213669 DOI: 10.3816/Cgc.2009.N.009 |
0.338 |
|
| 2009 |
Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. The Lancet. Oncology. 10: 233-9. PMID 19213602 DOI: 10.1016/S1470-2045(08)70340-1 |
0.359 |
|
| 2009 |
Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Research. 69: 958-66. PMID 19176386 DOI: 10.1158/0008-5472.CAN-08-2216 |
0.307 |
|
| 2009 |
De Bono JS, Parker C, Scher HI, Montgomery RB, Miller MC, Tissing H, Doyle GV, Terstappen LWWM, Pienta KJ, Raghavan D. Quantitative analysis of circulating tumor cells as a survival predictor in metastatic castration-resistant prostate cancer: Missing parts in a superb study Clinical Cancer Research. 15: 1504. DOI: 10.1158/1078-0432.CCR-09-0006 |
0.359 |
|
| 2008 |
Yossepowitch O, Bianco FJ, Eggener SE, Eastman JA, Scher HI, Scardino PT. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy: Editorial comment International Braz J Urol. 34: 791. |
0.351 |
|
| Show low-probability matches. |